cas 1935196-58-9|| where to buy 6-chloro-3-iodo-1H-pyrazolo[3,4-b]pyrazine

Produktname:6-chloro-3-iodo-1H-pyrazolo[3,4-b]pyrazine

IUPAC Name:6-chloro-3-iodo-1H-pyrazolo[3,4-b]pyrazine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM325847-250mg	in stock	ȯƛ
CM325847-1g	in stock	Ȗȅƥ
CM325847-5g	in stock	ǫƃƥ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1935196-58-9 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1935196-58-9; Molekulare Formel:C5H2ClIN4; Schmelzpunkt:-; SMILES-Code:IC1C2C(=NC(=CN=2)Cl)NN=1; Dichte:

: Katalognummer:CM325847; Molekulargewicht:280.45; Siedepunkt:; Mdl-Nr.:MFCD26521481; Lagerung:Keep in a tight container and store at 2°C~8°C

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Pyrazines; Pyrazine is a heterocyclic aromatic organic compound with chemical formula C4H4N2. The marketed pyrazine drugs are mainly distributed in the field of anti-tumor and anti-infection. In recent years, there have been many new drugs in various fields, and there are some new target drugs worthy of attention.; pyrazine,pyrazine price; if you want to know the latest news about pyrazine and pyrazine price, please come to our website and get a quote for free.

: GDC-1971; Protein tyrosine phosphatase SHP2 mediates RAS-driven MAPK signaling and has emerged in recent years as a target of interest in oncology, both for treating with a single agent and in combination with a KRAS inhibitor. GDC-1971 (formerly RLY-1971) is a SHP2 inhibitor currently in clinical trials in combination with KRAS G12C inhibitor divarasib (GDC-6036) for the treatment of solid tumors driven by a KRAS G12C mutation.